Chimeric antigen receptor (CAR) T cell therapy is a form of T cell engineering where T cells are obtained from a patient and engineered in a laboratory to better kill the patient's cancer cells. Specifically, CAR T cells are modified to express a receptor on their surface that recognizes the specific antigen present on the patient's cancer cells.
-
DATE: December 012, 2018TIME: 08:00 PSTImmunotherapy is a powerful treatment that harnesses the body’s immune system in the fight against cancer. With optimized cell therapy,...
There is considerable excitement surrounding the treatment potential of T cell immunotherapies. Amongst these, CAR-T cells have demonstrated impressive therapeutic efficacy in a subset of hem...
DATE: September 18,2018TIME: 08:00am PDT, 11:00am EDT CRISPR-Cas9 gene editing strategies have revolutionized our ability to engineer the genomes of diverse cell types and sp...
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
DATE: November 7, 2017 TIME: 10:00AM PSTChimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in...
DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T c...
Regenerative medicine therapeutics aimed at restoring normal cell function due to trauma and disease are gaining increasing momentum in clinical trials. For this purpose, lentivirus-based gen...